(Q41905474)

13 October 2017

Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer (English)

1 reference

non-small-cell lung carcinoma

13 October 2017

1 reference

1 reference

7

1 reference

13 October 2017

W Zoli

1

1 reference

13 October 2017

L Ricotti

2

1 reference

13 October 2017

M Dal Susino

3

1 reference

13 October 2017

F Barzanti

4

1 reference

13 October 2017

G L Frassineti

5

1 reference

13 October 2017

S Folli

6

1 reference

13 October 2017

F Bacci

8

1 reference

13 October 2017

D Amadori

9

1 reference

13 October 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

British Journal of Cancer

13 October 2017

1 reference

13 October 2017

81

1 reference

13 October 2017

4

1 reference

13 October 2017

609-615

1 reference

Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial

13 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Molecular and biological features of two new human squamous and adenocarcinoma of the lung cell lines

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Experience with new chemotherapeutic agents in non-small cell lung cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Paclitaxel plus doxorubicin in breast cancer: an Italian experience

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Single-agent activity of gemcitabine in advanced non-small cell lung cancer.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

New chemotherapeutic agents in non-small-cell lung cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Interaction between cisplatin and gemcitabine in vitro and in vivo.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

New colorimetric cytotoxicity assay for anticancer-drug screening

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Combination chemotherapy in vitro with adriamycin. Observations of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362882

Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial

5 June 2018

1 reference

12 December 2020

In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines

1 reference

12 December 2020

Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro

1 reference

12 December 2020

Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial

1 reference

12 December 2020

Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells

1 reference

12 December 2020

Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen

1 reference

12 December 2020

Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines

1 reference

12 December 2020

New chemotherapeutic agents in the treatment of non-small cell lung cancer: the Australian experience

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690737

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6690737

1 reference

13 October 2017

1 reference

13 October 2017

PubMed publication ID

10574245

1 reference